Alnylam, Medicines Co. tout early results for RNAi PCSK9 contender; Ex-Prosensa chief joins Asceneuron;

@FierceBiotech: KIT team points pancreatic cancer therapy toward clinical trials. FierceBiotechResearch article | Follow @FierceBiotech

@JohnCFierce: Ex-Lumena gang pilots new course at Amplyx with antifungal R&D, $40.5M. Report | Follow @JohnCFierce

@DamianFierce: $HZNP "is threatening $ESRX's profiteering and exposing ... a lack of care for patients and respect for physicians." Release | Follow @DamianFierce

> Alnylam Pharmaceuticals ($ALNY) and partner the Medicines Company ($MDCO) said their in-development RNAi treatment charted a sustained reduction of bad cholesterol in an ongoing Phase I trial. Like recently approved medicines from Sanofi ($SNY) and Amgen ($AMGN), the medicine targets PCSK9 to slash LDL cholesterol but is designed to be dosed much less frequently. More

> Hans Schikan, the former CEO of Prosensa, has been named chairman of Switzerland's Asceneuron. Release

> Zurich-based Kuros Biosurgery AG has added CHF 5 million to its latest fundraising, bringing the total to CHF 20 million. Release

> As Sanofi struggles to keep its diabetes business competitive, rival Novo Nordisk ($NVO) is snatching up more market share. Story

Medical Device News

@FierceMedDev: Medtronic reports strong leadless pacemaker data as it races St. Jude to FDA approval. More | Follow @FierceMedDev

@VarunSaxena2: IYCMI from FierceDrugDelivery: Physicians call for novel abuse-deterrent opioid agonist/antagonist formulations in survey. Article | Follow @VarunSaxena2

@EmilyWFierce: Theranos and Safeway split after $350M deal, code-named "T-Rex," falls through. More from the WSJ | Follow @EmilyWFierce

> AliveCor adds former Google exec as CEO to further consumer ECG push. Articles

> Stanford engineers develop touch-free ultrasound device for tumor detection. More

Pharma News

@FiercePharma: GeneOne, Inovio's MERS vaccine enters PhI at Walter Reed. Story | Follow @FiercePharma

@EricPFierce: ICYMI: #Novo makes sure Denmark gets some of the action as it starts massive build up. More | Follow @EricPFierce

@CarlyHFierce: $GSK shoots for diabetes-esque platform approach with new respiratory med in hand. Article | Follow @CarlyHFierce

> Bondholders bail on Valeant amid cash flow concerns. More

> Sources: Novartis faces yet another sanction in Japan. Article

Biotech Research News

> MD Anderson group tracks 'modest' impact of lymphoma drug. Item

> Warp Drive Bio constructs a new cancer R&D tech platform. Story

> Microbiome study highlights bacterial strategy for treating severe diarrhea. News

> Case Western researchers spotlight role of rapid protein movement in hearing loss. More

> KIT team points pancreatic cancer therapy toward clinical trials. Article

Vaccines News

> GeneOne, Inovio's MERS vaccine enters PhI at Walter Reed. News

> MenAfriVac succeeds in sub-Saharan Africa, but the fight isn't over yet. More

> James Cook University researcher wins $2M Gates grant for malaria vaccine development. Story

> Novavax kicks off PhIII trial for its RSV vaccine. Article

> EMA safety review raises no issues with HPV vaccines from Merck, GSK. Report

Pharma Marketing News

> $1-per-pill alternative to Turing drug gets 'overwhelming' response: Imprimis CEO. Article

> Medivation's Xtandi sales force due for hiring, revamp as urology push falls flat. Report

> GSK shoots for diabetes-esque platform approach with new respiratory med in hand. More

> Allergan counting on January formulary boost to jump-start Namzaric launch. Story

> AstraZeneca holds on to purple Nexium trademark with early court win. Article

Suggested Articles

Outgoing BIO Chair John Maraganore and his successor, Jeremy Levin, reflected on drug pricing, its drivers and its place in the innovation ecosystem.

The study is assessing the effect of the oral AXL inhibitor when given to elderly AML patients in combination with low-intensity chemotherapy.

The proportion of patients who had a greater than 1 g/dL increase in hemoglobin is down on GBT’s prior update but still superior to placebo.